Peptide research evidence, stack analysis & UK regulatory context
Evidence-led summaries of peptide combinations, mechanisms, study models, safety uncertainties and translational limitations. Not dosing advice, not medical advice, and not a protocol for human or animal use.
Educational research-literacy content only. PeptideStacks summarises published evidence, mechanisms, study models, regulatory context and translational limitations for peptide-related research. It does not provide medical advice, dosing recommendations, sourcing advice, self-administration instructions, or protocols for human or animal use. See our medical disclaimer and responsible information policy.
Explore the platform
29 peptide monographs · 22 stack evidence reviews · 12 comparisons.
Stack evidence reviews
Combination evidence with conservative grading and direct-vs-inferred labelling.
Peptide monographs
Per-peptide evidence summaries — mechanism, human-data status, regulatory context.
Evidence grading A–X
How we grade strength of evidence — conservatively, by default.
UK regulation hub
What UK regulators, legislation and anti-doping bodies say, quoted and dated.
Safety & quality hub
Contamination, sterility, immunogenicity, counterfeit supply chains.
Mechanism maps
GH axis, angiogenesis, NF-κB, AMPK, melanocortin, incretin & more.
Claim red flags
Marketing patterns, fake citation tactics, synergy that wasn’t demonstrated.
Research tools
Evidence strength checker, evidence-level classifier, PubMed search builder.
Featured stack evidence reviews
Each review carries an evidence dashboard — grade, human-data status, direct-vs-inferred combination evidence and translational risk.
BPC-157 + TB-500 + GHK-Cu — Research Evidence Review: Tissue-Repair & Remodelling Mechanisms
Evidence review of BPC-157, TB-500 and GHK-Cu for tissue repair: no study of the three together, one rat study of two found no added benefit, and little human evidence.
BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits
Evidence review of BPC-157 with TB-500: one rat study of the two together, one three-patient human report with other drugs, and what is unknown.
CJC-1295 + Ipamorelin + Tesamorelin — Research Evidence Review: GH Axis Mechanisms & Study Limitations
Evidence review of CJC-1295, ipamorelin and tesamorelin on the growth hormone axis: what has been studied in people, what the tesamorelin label says, and what is unknown.
CagriSema (Semaglutide + Cagrilintide) — Evidence Review
Evidence review of semaglutide plus cagrilintide (CagriSema): what the REDEFINE and REIMAGINE trials found, what is unknown, and the risks. Not a use protocol.
Epitalon + Humanin + MOTS-c — Research Evidence Review: What Has Been Studied
Evidence review of Epitalon, Humanin and MOTS-c: lifespan results in mice, small human epitalon reports, no study of the three together, and what is unknown.
KPV + LL-37 — Research Evidence Review: Mucosal & Antimicrobial Mechanisms
Evidence review of KPV and LL-37: what has been studied in cells, mice and people, and what is unknown. No study of the two together was found.
How to use this site responsibly
1. Read the evidence dashboard
Peptide and stack pages carry a dashboard showing grade, human-data status and translational risk. Stack dashboards also show whether the combination has direct evidence.
2. Check for direct combination data
Most stacks are inferred from monotherapy literature. We say so explicitly when a combination has not been directly studied.
3. Check the source and date
On every editorial page, a licensing or regulatory statement names its source and the date it was checked. Regulatory positions change, so check the date.
4. A study dose is not a recommendation
Where a page gives a dose, it is what a named study, trial registration or label reports, for the people in it. PeptideStacks does not publish use protocols or dosing schedules.
Conservative grades by default
Most peptide stacks on this site sit at Grade C or below. Combination evidence is rarely higher than the monotherapy evidence supporting either component.
Dated regulatory sources
On every editorial page, licensing and regulatory statements are attributed to the regulator or label they come from and carry a date, so you can check them.
Misinformation flagged
A whole hub of common claim patterns — fake citations, assumed synergy, before-and-after framing — and how to read past them.
Recent research syntheses
Editorial syntheses of the recent literature, with conservative framing and explicit limitations.
2026-05-21
Triple Incretin Agonism — Retatrutide and the GLP-1 / GIP / Glucagon Evidence Base
Critical research-literacy review of the GLP-1 / GIP / glucagon triple-agonist class — receptor pharmacology, Phase II and III trial evidence for retatrutide, comparison with tirzepatide, and the UK regulatory framing.
2026-05-21
Peptide Stacking Fundamentals — What 'Stack' Means in the Research Literature
An evidence-literacy introduction to what peptide stacking means in published research, when combination evidence is direct vs inferred, and how to read a stack page on PeptideStacks responsibly.
2026-05-21
UK Peptide Regulation 2026 — Official Statements, Dated and Sourced
Dated statements from the MHRA, NICE, the EMA, US FDA labels, WADA and UKAD about compounds covered on this site, each attributed and linked. Not legal advice.
Trust & transparency
Frequently asked questions
Is this medical advice?
No. PeptideStacks publishes evidence summaries for research literacy. For health concerns, consult a registered clinician.
Do you provide dosing protocols?
No. Where a page gives a dose, it is what a named study, trial registration or label reports, with a link to the source. We do not publish recommended doses, cycles, titration schedules or use protocols.
What do you say about UK medicines law?
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme. Background is in our regulation hub.
What does 'research use only' on a product label tell me?
It is wording chosen by the seller. It is not a test result and does not tell you what a product contains. This site gives no legal advice.
How are evidence grades assigned?
Conservatively, by rules set out on our methodology page. Most stacks sit at Grade C or lower because combination evidence is rarely robust.
Why don't animal studies prove a human effect?
Animals differ from people in absorption, metabolism and receptors, so a result in an animal may not hold in a person. Animal evidence can suggest a mechanism but does not show a human effect.
Evidence updates
Subscribe to hear when pages change. Updates to the evidence base on a peptide or combination, such as new trial data, regulatory statements or safety signals, are recorded in the changelog.
Sister sites & sponsor
Paid sponsorPeptideAuthority.co.uk
Per-peptide research monographs — companion long-form reference.
PeptideBarn.co.ukSponsor
UK research-grade peptide supply — for laboratory use only.
Editorial independent — see our conflict-of-interest disclosure.
Comparisons
Side-by-side evidence comparisons of peptides discussed together in research and online — mechanisms, evidence, dated regulatory statements, safety uncertainty.
Browse all comparisons